Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-723P (RNA, U6 small nuclear 723, pseudogene)** is a processed pseudogene of the U6 small nuclear RNA (snRNA) gene family[1][7]. U6 snRNA is a core component of the spliceosome complex, essential for pre-mRNA splicing in eukaryotic cells[3][5][12]. However, **RNU6-723P** itself is a pseudogene, meaning it is a genomic copy of a functional U6 small nuclear RNA gene that is typically non-functional and not transcribed into a functional product[1][9]. Pseudogenes like RNU6-723P generally do not encode proteins or active RNAs, though some pseudogenes can play regulatory roles via non-coding RNA mechanisms (e.g., acting as microRNA decoys or sources of regulatory RNAs in some contexts)[2][4]. There is no evidence that RNU6-723P functions as a therapeutic target (such as a receptor, enzyme, transporter, or transcription factor) or that it is implicated directly in human disease, drug interaction, or clinically relevant biomarkers[1][7][9]. Its main significance is as a genomic marker of retrotransposition events among small nuclear RNA genes in the genome[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 723, pseudogene (RNU6-723P).